MAGELLAN LONGEVITY
HomeResearchStudy library › ApoB-containing lipoproteins: count, type, size, and risk of…
Study summary · Cardiovascular & vascular aging

Does the type or size of apoB-containing lipoprotein particles add predictive value for coronary artery disease (CAD) beyond the total apoB concentration?

In one paragraph

NMR Lipoprotein Particle Test (Eur Heart J 2025, PMID 40289348) — lp(a) showed a robust association even after apoB-P adjustment (HR: 1.18) and provided independent prognostic value for CAD (AUC: 0.769 vs 0.774, P <.001). The abstract for NMR Lipoprotein Particle Test states no limitations.

Source: Eur Heart J 2025, PMID 40289348 ↗ · Research map · How Magellan grades evidence · evidence confidence: medium

Eur Heart J · 2025 · PMID 40289348 · DOI 10.1093/eurheartj/ehaf207

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Total apoB particle count is the primary indicator of atherosclerotic risk, with Lp(a) providing additional independent predictive value, while particle type or size offers little extra insight.

The question

Does the type or size of apoB-containing lipoprotein particles add predictive value for coronary artery disease (CAD) beyond the total apoB concentration?

What they tested

The study implicitly hypothesizes that the type or size of apoB particles might offer additional predictive value for CAD beyond the total apoB particle count.

How they did it

A prospective analysis was conducted on 207,368 UK Biobank participants without prior atherosclerotic disease, diabetes, or active lipid-lowering therapy. Multivariable-adjusted Cox regression models were used to assess the association between incident CAD and nuclear magnetic resonance-measured apoB-P, concentrations of individual lipoprotein classes (VLDL, LDL), size subclasses, average particle diameter, and immunoassay-measured lipoprotein(a) [Lp(a)].

What they found

A one standard deviation (SD) increase in apoB-P was associated with a 33% higher CAD risk (HR: 1.33). VLDL particles showed a higher per-particle risk (HR per 100 nmol/L: 1.22) compared to LDL (HR per 100 nmol/L: 1.07), but this difference was balanced when considering relative particle abundance (LDL 91% vs VLDL 9% of total apoB-P), resulting in respective HR per 1-SD of 1.09 for LDL and 1.24 for VLDL. Particle diameter or size subclasses were not associated with CAD after apoB-P adjustment. Lp(a) showed a robust association even after apoB-P adjustment (HR: 1.18) and provided independent prognostic value for CAD (AUC: 0.769 vs 0.774, P < .001).

Hazard Ratio for CAD per 1-SD Increase in Lipoprotein Parameters
Values shown: Hazard Ratio
apoB-P1.33
VLDL particles (per 1-SD)1.24
LDL particles (per 1-SD)1.09
Lp(a)1.18

A one standard deviation increase in apoB-P was associated with a 33% higher CAD risk. VLDL and LDL particles, when adjusted for relative abundance, showed HRs of 1.24 and 1.09 respectively per 1-SD. Lp(a) also showed an independent association with CAD risk (HR: 1.18).

What it means

The total count of apoB-containing lipoprotein particles most accurately reflects lipid-related atherosclerotic risk, and this risk is largely unaffected by the major particle type (VLDL, LDL) or size. An elevated count of Lp(a) adds additional risk, suggesting that assessing atherogenic risk from dyslipidemia is best done by considering both apoB-P and Lp(a) concentrations.

Limitations

The abstract does not explicitly state any limitations of the study.

Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.

“atherosclerotic risk is most accurately reflected by the total count of apoB particles”— from the published abstract, Eur Heart J 2025

The paper at a glance

TitleApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease
JournalEur Heart J
Year2025
PMID40289348 ↗
DOI10.1093/eurheartj/ehaf207 ↗
TopicCardiovascular & vascular aging

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

NMR Lipoprotein Particle Test

Particle counts refine cardiovascular risk. Research relevant to this mechanism is indexed on PubMed and linked below; it describes the mechanism rather than this specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Does the type or size of apoB-containing lipoprotein particles add predictive value for coronary artery disease (CAD) beyond the total apoB concentration? [Plain-English summary of Eur Heart J 2025, PMID 40289348, DOI 10.1093/eurheartj/ehaf207]. Magellan Longevity. https://magellanlongevity.com/study/d40289348.html
BibTeX
@misc{magellan_d40289348, title = {Does the type or size of apoB-containing lipoprotein particles add predictive value for coronary artery disease (CAD) beyond the total apoB concentration?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d40289348.html}}, note = {Plain-English summary of PubMed PMID 40289348; DOI 10.1093/eurheartj/ehaf207; Eur Heart J 2025. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d40289348.html

Related studies in the Magellan library

All 67 Magellan summaries on cardiovascular & vascular aging →

How this summary was made. Every section above restates what the published abstract of PMID 40289348 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.